109 related articles for article (PubMed ID: 24313590)
1. Lack of expression of an alternative CD20 transcript variant in circulating B cells from patients with pemphigus.
Gamonet C; Ferrand C; Colliou N; Musette P; Joly P; Girardin M; Humbert P; Aubin F
Exp Dermatol; 2014 Jan; 23(1):66-7. PubMed ID: 24313590
[TBL] [Abstract][Full Text] [Related]
2. The need for markers and predictors of Rituximab treatment resistance.
Sitaru C; Thiel J
Exp Dermatol; 2014 Apr; 23(4):236-7. PubMed ID: 24450995
[TBL] [Abstract][Full Text] [Related]
3. CD20 alternative splicing isoform generates immunogenic CD4 helper T epitopes.
Vauchy C; Gamonet C; Ferrand C; Daguindau E; Galaine J; Beziaud L; Chauchet A; Henry Dunand CJ; Deschamps M; Rohrlich PS; Borg C; Adotevi O; Godet Y
Int J Cancer; 2015 Jul; 137(1):116-26. PubMed ID: 25449106
[TBL] [Abstract][Full Text] [Related]
4. Response in patients with pemphigus vulgaris to rituximab therapy. Basis of the biology of B cells.
Leuci S; Levine D; Zhang J; Razzaque Ahmed A
G Ital Dermatol Venereol; 2009 Aug; 144(4):379-409. PubMed ID: 19755943
[TBL] [Abstract][Full Text] [Related]
5. Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus.
Arin MJ; Engert A; Krieg T; Hunzelmann N
Br J Dermatol; 2005 Sep; 153(3):620-5. PubMed ID: 16120153
[TBL] [Abstract][Full Text] [Related]
6. [Treatment of pemphigus with rituximab].
Li J; Zheng HY; Liu YH
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Feb; 31(1):107-10. PubMed ID: 19317073
[TBL] [Abstract][Full Text] [Related]
7. Preliminary In Vitro Effects of CD8+ T Lymphocyte Specific for the CD20 Alternative Splicing D393-CD20 Peptide Expressed on Burkitt Lymphoma Cells.
Chegni H; Hassan ZM; Nisini R; Ebrahimi M; Sabouni F
Asian Pac J Cancer Prev; 2019 Aug; 20(8):2563-2568. PubMed ID: 31450932
[TBL] [Abstract][Full Text] [Related]
8. Combined treatment with immunoadsorption and rituximab leads to fast and prolonged clinical remission in difficult-to-treat pemphigus vulgaris.
Behzad M; Möbs C; Kneisel A; Möller M; Hoyer J; Hertl M; Eming R
Br J Dermatol; 2012 Apr; 166(4):844-52. PubMed ID: 22092243
[TBL] [Abstract][Full Text] [Related]
9. The efficacy and safety of rituximab in refractory pemphigus: a review of case reports.
Allen KJ; Wolverton SE
J Drugs Dermatol; 2007 Sep; 6(9):883-9. PubMed ID: 17941359
[TBL] [Abstract][Full Text] [Related]
10. Rituximab: a monoclonal antibody to CD20 used in the treatment of pemphigus vulgaris.
El Tal AK; Posner MR; Spigelman Z; Ahmed AR
J Am Acad Dermatol; 2006 Sep; 55(3):449-59. PubMed ID: 16908351
[TBL] [Abstract][Full Text] [Related]
11. Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab).
Morrison LH
J Am Acad Dermatol; 2004 Nov; 51(5):817-9. PubMed ID: 15523367
[TBL] [Abstract][Full Text] [Related]
12. A prospective study on clinical response and cell-mediated immunity of pemphigus patients treated with rituximab.
Leshem YA; David M; Hodak E; Waitman DA; Vardy D; Israeli M; Eskin-Schwartz M; Bergman R; Mimouni D
Arch Dermatol Res; 2014 Jan; 306(1):67-74. PubMed ID: 23591742
[TBL] [Abstract][Full Text] [Related]
13. B-cell depletion immunotherapy in pemphigus: effects on cellular and humoral immune responses.
Mouquet H; Musette P; Gougeon ML; Jacquot S; Lemercier B; Lim A; Gilbert D; Dutot I; Roujeau JC; D'Incan M; Bedane C; Tron F; Joly P
J Invest Dermatol; 2008 Dec; 128(12):2859-69. PubMed ID: 18563177
[TBL] [Abstract][Full Text] [Related]
14. Comparison of immunological parameters in patients with pemphigus vulgaris following rituximab and IVIG therapy.
Feldman RJ; Christen WG; Ahmed AR
Br J Dermatol; 2012 Mar; 166(3):511-7. PubMed ID: 21967407
[TBL] [Abstract][Full Text] [Related]
15. Low-dose rituximab is effective in pemphigus.
Horváth B; Huizinga J; Pas HH; Mulder AB; Jonkman MF
Br J Dermatol; 2012 Feb; 166(2):405-12. PubMed ID: 21967609
[TBL] [Abstract][Full Text] [Related]
16. Identification of an alternative CD20 transcript variant in B-cell malignancies coding for a novel protein associated to rituximab resistance.
Henry C; Deschamps M; Rohrlich PS; Pallandre JR; Rémy-Martin JP; Callanan M; Traverse-Glehen A; GrandClément C; Garnache-Ottou F; Gressin R; Deconinck E; Salles G; Robinet E; Tiberghien P; Borg C; Ferrand C
Blood; 2010 Mar; 115(12):2420-9. PubMed ID: 20089966
[TBL] [Abstract][Full Text] [Related]
17. Current therapy of the pemphigus group.
Kasperkiewicz M; Schmidt E; Zillikens D
Clin Dermatol; 2012; 30(1):84-94. PubMed ID: 22137231
[TBL] [Abstract][Full Text] [Related]
18. Rituximab treatment in pemphigus vulgaris: effect on circulating Tregs.
El-Zawahry B; Bassiouny D; Hegazy R; Gawdat H; Shalaby S; Khorshied M; Saleh MA
Arch Dermatol Res; 2017 Sep; 309(7):551-556. PubMed ID: 28631092
[TBL] [Abstract][Full Text] [Related]
19. Rituximab immunotherapy in pemphigus: therapeutic effects beyond B-cell depletion.
Zambruno G; Borradori L
J Invest Dermatol; 2008 Dec; 128(12):2745-7. PubMed ID: 18997839
[TBL] [Abstract][Full Text] [Related]
20. Follow-up data of 10 patients with B-cell non-Hodgkin lymphoma with a CD20-negative phenotypic change after rituximab-containing therapy.
Maeshima AM; Taniguchi H; Fukuhara S; Morikawa N; Munakata W; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Tsuda H
Am J Surg Pathol; 2013 Apr; 37(4):563-70. PubMed ID: 23426122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
